Newsroom | 1397 results

EL SEGUNDO, Calif.--(BUSINESS WIRE)--A federal court ruled MetLife wrongly denied long-term disability benefits, setting a key precedent for long-haul COVID ERISA claims....

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Southern Research and London-based Pathogenus Consulting have signed a three-year partnership that will allow both organizations to capitalize on growing research opportunities around the world. "We’ve seen clear momentum in our work with partners outside the United States, especially with Japan and European pharmaceutical companies, and the opportunity to broaden that footprint is both exciting and timely,” said Fusataka Koide, senior director of global clien...

NEW YORK--(BUSINESS WIRE)--PFE Q4 2025 Earnings Release...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Found...

MIAMI--(BUSINESS WIRE)--A new study from the University of Miami Public Health Policy Lab and the AHF Global Public Health Institute sheds light on why public trust broke down during the COVID-19 pandemic—and what can be done to rebuild it before the next health emergency. Drawing on interviews with government, academic, and private-sector leaders across Florida, the study found that distrust in public health grew due to a lack of transparency, political tensions, and inconsistent communication...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare,” said Daniel O’Day, C...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial guidance(2). The accompanying presentation can be found at www.pfizer.com/investors. FULL-YEAR 2026 REVENUE GUIDANCE(2) Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance(2) is revised to app...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer...

WALTON OAKS--(BUSINESS WIRE)--Pfizer Ltd today shared findings from a survey developed and funded by Pfizer but conducted independently by OnePoll, with 2,000 people aged over 65 across the UK between 21-27 November 2025, which reveals how older adult respondents see avoiding respiratory infections (COVID, pneumonia, RSV, flu) as essential to protecting both their freedom and their role at the heart of family and community life.1 The survey underscores the strong motivation older adult responde...